Skip to Content
Søk Menu

Bimekixizumab: Blokade av både IL-17A og IL-17F. Hva betyr det for oss dermatologer og våre pasienter?

EUs godkjenning av bimekizumab (BIMZELX®) for behandling av moderat til alvorlig plakkpsoriasis den 31. august 2021 ble endelig godkjent av Norge den 22. november 2022, noe som gjør landet til det siste i Scandinavia til å godkjenne produktet.

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Relatert innhold

Karina Winther Andersen

Patients’ Gender Roles and Coping Strategies are Important Topics in Health Care Professionals Dialogue with Crohn’s Patients

/ Karina Winther Andersen
CrohnsIBDSeksuell helse Play the Video 5:53

The Best Medications in Psoriasis

/ Andrew Blauvelt
Psoriasis Play the Video 5:37

Reproductive Safety of Novel Small Molecules in IBD

/ Christian Philipp Selinger
GraviditetIBD Play the Video 5:00

Managing Risks with Newer Oral Small Molecules in Patients with IBD

/ Parakkal Deepak
IBDJAK-hemmere Play the Video 10:38

Increased Incidence of Comorbid Diseases 10 years Prior to IBD Diagnosis

/ Anthony C. Ebert
ECCO24IBD Play the Video 6:47
Gorm Roager Madsen

Periodontitis Seems to Be Linked to Increased IBD Disease Activity and Disability

/ Gorm Roager Madsen
ECCO24IBD Play the Video 4:05
Tanja Toivonen

A New Tool for IBD Nurses to Support IBD Patients Has Proven to Work

/ Tanja Toivonen
ECCO24IBDTeknologi Play the Video 4:11
Erik Lundqvist

Prognosis in Rectal Cancer Patients With and Without IBD is Time-Dependent

/ Erik Lundqvist
ECCO24IBD Play the Video 8:08
Jonas Julius Rudbæk

Association Between Inflammatory Markers and Early Onset IBD May Be Present Shortly After Birth

/ Jonas Julius Rudbæk
ECCO24IBD Play the Video 07:19
Back to top